Drugs / SR-T100
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01676792 | Apr 2011 → Apr 2013 | anogenital human papillomavirus infection, vulvar intraepithelial neoplasia | National Cheng-Kung University Hospital | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02085395 | Nov 2007 → Apr 2010 | Bowen disease of the skin, actinic keratosis | G&E Herbal Biotechnology Co., LTD | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01493921 | Oct 2011 → Nov 2015 | actinic keratosis | G&E Herbal Biotechnology Co., LTD | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT01796795 Comparator | Sep 2030 → Apr 2033 | common wart | G&E Herbal Biotechnology Co., LTD | Suspended | No outcome recorded |
| Phase 2 | NCT01796821 Comparator | Aug 2014 → Sep 2018 | anogenital human papillomavirus infection | G&E Herbal Biotechnology Co., LTD | Completed | No outcome recorded |
| Phase 2 | NCT01516515 Comparator | Feb 2013 → Dec 2017 | actinic keratosis | G&E Herbal Biotechnology Co., LTD | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SR-T100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01676792 ↗ |
| Known as | SR-T100 gel | “SR-T100 gel” NCT01676792 ↗ |
| Route | Topical | “self-apply approximately 0.3\~0.5g of SR-T100 gel on 25 cm squared treatment area” NCT01493921 ↗ |